Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article

Med Arch. 2021; 75(5): 347-350


miRNA-21 as Reliable Serum Diagnostic Biomarker Candidate for Metastatic Progressive Prostate Cancer: Meta-analysis Approach

Kurnia Penta Seputra1, Basuki Bambang Purnomo, Hani Susianti, Handono Kalim, Athaya Febriantyo Purnomo.

Abstract
Background: Prostate cancer is the second leading cause of cancer death in men, moreover when it develops metastasis. However, PSA detection in serum as current gold standard to measure disease progressivity had wide variability leading to confounding outcomes. MicroRNA-21 has diagnostic values for cancer over period of time researched, yet results are still inconclusive. Objective: The aim of the study was to conduct recent meta-analysis to assess reliability of miRNA-21 as diagnostic biomarker especially in progressivity of prostate cancer. Methods: Published papers from PubMed, Science Direct, and Embase” as of 1 July 2021 assessing circulating miRNA-21 in progressivity of prostate cancer patients were analyzed using Comprehensive Meta-Analysis tool. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR) and SROC assessed with 95 % confidence intervals were estimated using fixed-effects or random-effects models. Results: In total, we included 6 papers total of 651 samples reporting miRNA-21 capability of detecting progressive prostate cancer. The pooled sensitivity and specificity showed 0.91 (95% CI 0.88-0.94, I2=0%) and 0.89 (95% CI 0.85-0.92, I2=44.8%), respectively. Positive and negative likelihood ratio showed 7.18 (95% CI 4.31-11.96, I2=56%) and 0.11 (95% CI 0.07-0.16, I2=11.8%). SROC were assessed and got Area Under Curve around 97.4%. Conclusion: miRNA-21 could serve as biomarkers of prostate cancer progressivity since remarkable diagnostic value of circulating miRNA-21 in prostate cancer metastasis process.

Key words: miRNA-21, biomarker, prostate, cancer, progressivity, metastatic.



Similar Articles

Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK
Surgical oncology clinics of North America. 2022; 31(1): 109-126

Financial Toxicity and Shared Decision Making in Oncology.
Greenup RA
Surgical oncology clinics of North America. 2022; 31(1): 1-7

Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer.
Wu Q, Li Q, Zhu W, Zhang X, Li H
Molecular medicine reports. 2022; 25(1):

Construction of a sensitive and selective plasmonic biosensor for prostate specific antigen by combining magnetic molecularly-imprinted polymer and surface-enhanced Raman spectroscopy.
Turan E, Zengin A, Suludere Z, Kalkan NĂ–, Tamer U
Talanta. 2022; 237(): 122926

Organelle-inspired supramolecular nanomedicine to precisely abolish liver tumor growth and metastasis.
Zhan J, Wang Y, Ma S, Qin Q, Wang L, Cai Y, Yang Z
Bioactive materials. 2022; 9(): 120-133


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites